China approves first antibody Covid treatment

The BRII-196/BRII-198 combination is intended to treat mild Covid-19 and “ common types ” of the disease in patients with high risk of developing severe illness, the National Medical Products Administration said in a statement.

The neutralizing antibody cocktail was approved for both adults and minors aged between 12 and 17 years.…

Visit the original:
ChinaPulse.com

Comments are closed.